2021
Effects of SSRI treatment on GABA and glutamate levels in an associative relearning paradigm
Spurny B, Vanicek T, Seiger R, Reed MB, Klöbl M, Ritter V, Unterholzner J, Godbersen GM, Silberbauer LR, Pacher D, Klug S, Konadu ME, Gryglewski G, Trattnig S, Bogner W, Lanzenberger R. Effects of SSRI treatment on GABA and glutamate levels in an associative relearning paradigm. NeuroImage 2021, 232: 117913. PMID: 33657450, PMCID: PMC7610796, DOI: 10.1016/j.neuroimage.2021.117913.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsGamma-aminobutyric acidMajor depressive disorderSerotonin reuptake inhibitorsSSRI treatmentPlacebo administrationReuptake inhibitorsGlutamatergic functionGlutamatergic neurotransmissionDepressive disorderNeuroplastic effectsSerotonergic systemNeurotransmitter systemsHealthy subjectsPsychiatric disordersImpaired cognitive flexibilityBrain regionsNeurotransmitter concentrationsCognitive functionWidespread symptomsMemory formationLast dayDisordersDownstream effectsTreatment
2019
Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression
Kautzky A, James GM, Philippe C, Baldinger-Melich P, Kraus C, Kranz GS, Vanicek T, Gryglewski G, Hartmann AM, Hahn A, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression. Translational Psychiatry 2019, 9: 5. PMID: 30664620, PMCID: PMC6341100, DOI: 10.1038/s41398-018-0308-2.Peer-Reviewed Original ResearchConceptsBrain-derived neurotrophic factor (BDNF) geneAffective disordersReceptor bindingSingle nucleotide polymorphismsPhenotype of depressionNeurotrophic factor geneSerotonin 1A receptor geneFunctional single nucleotide polymorphismsReceptor profileHealthy subjectsPET resultsRisk genotypesRs6265Multifactorial riskCortical regionsMixed modelsRisk allelesRs6295DisordersCortical surfaceReceptor geneReceptorsMolecular phenotypesHTR1ADepression
2018
Segmentation of hippocampal subfields and nuclei of the amygdala with major depressive disorder and healthy controls – preliminary findings
Vanicek T, Seiger R, Gryglewski G, Kautzky A, Klöbl M, Rischka L, Miles James G, S. Kranz G, Hahn A, Kasper S. Segmentation of hippocampal subfields and nuclei of the amygdala with major depressive disorder and healthy controls – preliminary findings. 2018 DOI: 10.26226/morressier.5b681762b56e9b005965c31f.Peer-Reviewed Original ResearchBrain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy
Spies M, James GM, Vraka C, Philippe C, Hienert M, Gryglewski G, Komorowski A, Kautzky A, Silberbauer L, Pichler V, Kranz GS, Nics L, Balber T, Baldinger-Melich P, Vanicek T, Spurny B, Winkler-Pjrek E, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Winkler D. Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy. Translational Psychiatry 2018, 8: 198. PMID: 30242221, PMCID: PMC6155094, DOI: 10.1038/s41398-018-0227-2.Peer-Reviewed Original ResearchConceptsBright light therapyMAO-A levelsBrain MAO-A levelsSeasonal affective disorderPositron emission tomographyMAO-A VTNon-seasonal depressionHealthy controlsLight therapyAffective disordersTreatment of SADMajor depressive disorderBrain monoamine oxidaseCerebral MAODepressive disorderSerotonergic systemPET scansHC groupMilder symptomsPatientsDistribution volumeEmission tomographyMonoamine oxidaseDisordersSignificant reduction